Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tropomyosin receptor kinase inhibitors: an updated patent review for 2016–2019

4 Mar 2020

Abstract excerpt

Introduction: Tropomyosin receptor kinases (Trks) control processes in the fields of growth, survival, and differentiation of neuronal processes. They also play a crucial role in neurodegenerative diseases as well as different types of cancer. Interest in developing Trk inhibitors to target NTRK fusion-driven cancers has escalated in the last decade, leading to the FDA approval of the pan-Trk inhibitors...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to HER2/EGFR in Cancer Research
Share to Quinazolinone synthesis and applications

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32129124
DOI: 10.1080/13543776.2020.1737011

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tropomyosin receptor kinase inhibitors: an updated patent review for 2016–2019PMID 32129124Read ↗

Type II & III inhibitors of tropomyosin receptor kinase (Trk): a 2020-2022 patent update.Semantic proximity Read ↗

Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancerSemantic proximity Read ↗

Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancersSemantic proximity Read ↗

Targeting TRK: A Fast Tracked Application of Precision Oncology and Future DirectionsSemantic proximity Read ↗

Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion CancerSemantic proximity Read ↗

Safety of current treatment options for NTRK fusion-positive cancersSemantic proximity Read ↗

Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomasSemantic proximity Read ↗

TRK inhibitor activity and resistance in TRK fusion-positive cancers in adults.Semantic proximity Read ↗

Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinibSemantic proximity Read ↗

Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusionSemantic proximity Read ↗

Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidenceSemantic proximity Read ↗

Selective type II TRK inhibitors overcome xDFG mutation mediated acquired resistance to the second-generation inhibitors selitrectinib and repotrectinibSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.